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Abstract
Background—After hematopoietic cell transplantation (HCT), polyoma-BK virus is associated 
with hemorrhagic cystitis and also with polyomavirus nephropathy (PVN). However, the true 
burden of post-HCT PVN is unknown because kidney biopsies are avoided due to their bleeding 
risk. The novel, non-invasive urinary PV-Haufen test detects PVN in kidney transplant recipients 
with >95% positive/negative predictive values. We hypothesized that the detection of PV-Haufen 
in voided urine samples–a positive PV-Haufen test–was also clinically significant after HCT.
Methods—We examined 21 suitable urine samples from 14 patients (median age 15 years, 71.4% 
male) who were selected from repositories for having varying degrees of BK-viremia (range 
0-1.0×108 copies/mL), hemorrhagic cystitis (present/absent) and data on kidney function. Urine 
samples were obtained a median of 88 days post-HCT.
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Results—PV-Haufen were detected in 5/14 patient (35.7%) and 7/21 (33.3%) urine samples, 
with histologic confirmation of PVN in one autopsy specimen. After a median of 285 days post-
HCT, patients with PV-Haufen had an increased risk of dialysis-dependent renal failure (p<0.05). 
All three dialysis-dependent patients had PV-Haufen and died. The presence of urinary PV-Haufen 
was not significantly correlated with hemorrhagic cystitis. From the 16 urines collected during 
BK-viremia, 43.8% were PV-Haufen positive and 56.2% negative. PV-Haufen were not present in 
the five urines from patients without concomitant BK-viremia.
Conclusions—In this proof-of-concept study, a positive PV-Haufen test was only seen in some 
patients with BK-viremia, and was not associated with hemorrhagic cystitis. The detection of PV-
Haufen suggests underlying PVN with an increased risk of kidney failure and dialysis.
INTRODUCTION
Chronic kidney disease (CKD) occurs in 20% of children after hematopoietic cell 
transplantation (HCT), and in most cases, an underlying cause is not apparent.1 
Understanding the mechanisms for CKD post-HCT could establish therapeutic targets and 
improve survival.2
One potential cause of CKD is polyomavirus nephropathy (PVN). After kidney 
transplantation, PVN is seen in approximately 5% of patients and can lead to chronic 
allograft failure and graft loss in up to 50% of cases.3 After HCT, polyoma-BK virus is often 
associated with hemorrhagic cystitis4, 5 and in sporadic cases with PVN, as documented in a 
few case reports.6-8 However, the true incidence of PVN post-HCT and its impact on CKD is 
unknown because kidney biopsies, the traditional method for establishing a definitive 
diagnosis,3, 9-11 are often avoided due to the high risk of bleeding.12 Thus, the question 
remains, does PVN contribute to CKD after HCT?
Laboratory tests, especially quantitative polymerase chain reaction (PCR) assays in the 
blood (viremia) or urine (viruria), are commonly used to assess immunosuppressed patients 
for the activation and replication of BK virus and their risk for viral disease. These PCR-
based screening protocols are well established in kidney transplant recipients in the context 
of PVN.13-15 However, similar to other latency-establishing DNA viruses such as CMV, the 
PCR-based detection of viral replication is insufficient for diagnosing disease, including 
PVN. For example, BK-viremia occurs in approximately 30% of kidney transplant recipients 
but only a subgroup of these viremic individuals develop PVN, which is why diagnostic 
confirmation of “definitive” PVN is traditionally established by renal biopsy.3, 9-11, 16 After 
HCT, BK-viremia is common and associated with hemorrhagic cystitis,4, 17 but in this 
patient population, the association between viremia and PVN is undetermined.
Recently, a novel, non-invasive urine-based test has been described in kidney transplant 
recipients to diagnose PVN accurately with >95% positive and negative predictive values. 
This assay was named the urinary PV-Haufen test.18 The rationale and significance of 
urinary PV-Haufen as biomarkers for PVN differs from conventional approaches. The PV-
Haufen test uses electron microscopy (EM) to detect dense, cast-like PV-aggregates in 
voided urine samples. PV-Haufen form in virally injured renal tubules in PVN, are flushed 
out of the kidneys, and appear in the urine as direct markers of intra-renal viral disease.18-21 
Laskin et al. Page 2
Transplantation. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thus, the urinary PV-Haufen test offers a more specific approach to diagnose intra-renal 
PVN that appears to be superior to conventional PCR-based assays. Our objective in this 
small, observational, non-intervention pilot study was to determine the clinical significance 
of urinary PV-Haufen shedding post-HCT: Is PVN based on a positive urinary PV-Haufen 
test seen in these patients and is PVN a potential cause for kidney failure and morbidity?
MATERIALS and METHODS
Study population and sample selection
We conducted a case-control study to evaluate the presence of urinary PV-Haufen in children 
and young adults after allogeneic HCT. Patients enrolled in ongoing, prospective specimen 
repositories at the Children's Hospital of Philadelphia (CHOP) and Cincinnati Children's 
Hospital Medical Center (CCHMC) had urine stored for later testing. For this pilot study, 
patients were selected if they had available urine samples fixed in paraformaldehyde and 
varying degrees of BK-viremia (by PCR), data on renal function and data on the presence or 
absence of hemorrhagic cystitis. Clinical information was recorded from April 2012-
September 2014, representing a time period where subjects had been enrolled into the 
repository studies. All participants gave written informed consent to use their samples and 
review their clinical information and the Institutional Review Boards at CHOP and CCHMC 
approved the research.
Detection of PV-Haufen
Urine samples (10-25 ml) were collected, fixed in a 1:1 ratio with 4% neutral buffered 
paraformaldehyde, and stored at 4 degrees C. PV-Haufen testing was performed at the 
University of North Carolina according to detailed previous descriptions using conventional 
negative staining EM.20 Briefly, PV-Haufen are defined as three-dimensional, dense, cast-
like, viral aggregates composed of six or more virions (Figure 1).18-20 To search for PV-
Haufen, urine samples were clarified, concentrated, and placed on an EM grid where the PV-
Haufen adhere by electrostatic binding.20 One EM grid was prepared for each patient's urine 
sample and examined by transmission EM (LEO EM-910, LEO Electron Microscopy, 
Thornwood, NY, accelerating voltage, 90-100 kV at 80,000-100,000x magnification) for a 
maximum of 30 minutes, according to previous descriptions.18 The examining pathologist 
was blinded to each patient's clinical information.
21 urine samples from 14 patients were included into the study; three urine samples with 
marked degradation were excluded. Two patients underwent autopsy two and five weeks 
after the last urinary PV-Haufen testing, respectively. No kidney tissue was available from 
the remaining 12 patients. Study results were qualitatively reported as either PV-Haufen 
present (one or more) or as PV-Haufen not detected/absent; quantitation of PV-Haufen 
shedding (number of PV-Haufen/mL of urine) was also reported, as previously described.20
Clinical and laboratory data
We included clinical and laboratory data for each patient from the start of transplant until the 
end of follow-up (September 30, 2014) or patient death, whichever came first. Clinical data 
included demographics, transplant characteristics, treatment for BK virus infection, 
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concomitant viral infections, development of acute graft versus host disease (GVHD), 
hemorrhagic cystitis, and kidney failure requiring dialysis. Hemorrhagic cystitis was defined 
as gross hematuria.17
Laboratory information obtained as part of clinical care (serum creatinine and BK virus PCR 
plasma testing) was recorded. At CCHMC, BK virus PCR screening was performed 
routinely in all patients, while at CHOP, BK virus PCR testing was done only for clinical 
indication. Creatinine-estimated glomerular filtration rate (eGFR) was calculated with the 
bedside Chronic Kidney Disease in Children (CKID) formula where eGFR (ml/min/1.73m2) 
= (0.413*baseline height (cm)/serum creatinine).22
Outcomes and statistical analyses
Continuous data were reported as medians (interquartile ranges (IQR) and categorical data 
as proportions. Clinical outcomes between patients with and without detectable PV-Haufen 
were compared using Wilcoxon rank-sum for continuous variables (eGFR) and Fisher exact 
test for categorical variables (hemorrhagic cystitis, need for dialysis, or death). Analyses 
were conducted using STATA software (version 12, College Station, Texas). A two-sided p-
value <0.05 was considered statistically significant.
RESULTS
Patient characteristics
Fourteen patients with 21 available urine samples were included into this pilot study. Seven 
patients had two separate urine samples tested for PV-Haufen and the remaining seven 
patients had one sample each. The median age of the patients was 15 years (IQR 10.8-25.5 
years) and 71.4% were male. Most of the patients underwent HCT for an indication of 
malignancy and received myeloablative conditioning which included cyclophosphamide. All 
patients received GVHD prophylaxis with cyclosporine. Patients were followed for a median 
of 285 days after transplant (IQR 162-396 days, range 87-815 days); clinical characteristics 
are shown in supplemental Table 1.
Urinary PV-Haufen test results
The PV-Haufen results are shown in Table 1. PV-Haufen were detected in 5/14 patients 
(35.7%) and 7/21 (33.3%) urine samples with quantitative assays ranging from 56 PV-
Haufen/mL to 4233/mL urine. Urine samples had been obtained a median of 88 days (IQR 
31-122 days, range 20-799 days) after HCT. In the seven patients with repeat urine testing, 
two patients had detectable PV-Haufen in both samples (PV-Haufen shedding persisted for 
84 and 267 days), two patients had PV-Haufen in only one out of two samples (PV-Haufen 
appeared 282 days after a previous negative sample in one patient and PV-Haufen were no 
longer detected after 28 days in the second patient) and three patients were negative for PV-
Haufen in two samples tested (separated by 32, 33, and 70 days).
BK-viremia was detected at 16/21 time points when urine was collected (median blood BK 
PCR of 227,520 copies/mL, IQR 26,933-1,534,841 copies/mL). From these 16 urine 
samples collected during BK-viremia, 7/16 (43.8%) were PV-Haufen positive (median blood 
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BK PCR of 1,206,325 copies/mL, IQR 43,520-1×108 copies/mL) and the remaining 9/16 
(56.2%) were negative for PV-Haufen (median blood BK PCR of 26,959 copies/mL, IQR 
6174-607,463 copies/mL). PV-Haufen were not present in the five urine samples obtained 
from patients without concomitant BK-viremia.
Association between qualitative PV-Haufen test results and clinical outcomes
Of the 14 patients, 10 (71.4%) developed hemorrhagic cystitis at a median of 27.5 days (IQR 
20-33 days) after transplant. Among the 10 patients with hemorrhagic cystitis, four (40.0%) 
had detectable PV-Haufen and six (60.0%) did not (p>0.99) at any point during observation.
All 14 patients had normal kidney function prior to HCT with a median creatinine-eGFR of 
118.9 ml/min/1.73m2 (IQR 105.6-142.1 ml/min/1.73m2). At last follow-up, immediately 
before dialysis initiation, or prior to death, the five patients with detectable PV-Haufen had a 
median creatinine-eGFR of 58.3 ml/min/1.73m2 (IQR 10.6-82.0 ml/min/1.73m2) and the 
nine patients without detectable PV-Haufen had a median creatinine-eGFR of 73.9 ml/min/
1.73m2 (IQR 59.6-105.6 ml/min/1.73m2, p=0.16).
Three patients (21.4%) developed dialysis-dependent kidney failure at a median of 153 days 
(IQR 130-796 days) after transplant. All three patients who received dialysis had detectable 
PV-Haufen while none of the nine patients without PV-Haufen required dialysis (p<0.05). A 
total of five patients (35.7%) died at a median of 162 days (IQR 150-264 days) after HCT. 
Among the patients who died, 3/5 (60.0%) had detectable PV-Haufen compared to 2/9 
(22.2%) surviving patients with a positive PV-Haufen test (p=0.27).
PV-Haufen results in the two patients undergoing autopsy (Figures 1 and 2)
Patient number 10 had abundant PV-Haufen shedding at 532 days after HCT (4233 PV-
Haufen/mL of urine) which persisted for 267 days (1128 PV-Haufen/mL urine at the time of 
second urine testing). The patient had histologic evidence of PVN at autopsy two weeks 
after last testing (Figure 1). The second patient (patient number 2) had markedly decreasing 
urinary PV-Haufen numbers during follow-up: first urine testing 27 days post-HCT with 507 
PV-Haufen/mL; subsequent urine sampling 84 days later with 56 PV-Haufen/mL urine. 
About five weeks after the second test, no histologic evidence of PVN was seen at autopsy.
DISCUSSION
Cast-like polyomavirus aggregates in voided urine samples, termed PV-Haufen, have been 
described as highly specific, non-invasive diagnostic biomarkers for PVN in kidney 
transplant recipients.10, 18, 20 The underlying concept–the detection of casts in voided urine 
samples as markers of intra-renal disease–is well established with red blood cell casts, for 
example, marking glomerulonephritis. Analogously, studies suggest that cast-like PV-
Haufen form in PVN in virally injured renal tubules in the presence of high uromodulin 
concentrations, similar to other casts.21 Singh et al tested for PV-Haufen in urine samples 
from a large cohort of patients without clinical or biopsy evidence of PVN and 21 primarily 
kidney transplant recipients with biopsy-proven PVN. The study included one PV-Haufen 
positive HCT recipient with biopsy-proven PVN and 15 HCT controls that were PV-Haufen 
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negative; seven patients presented with hemorrhagic cystitis. In Singh's study, PV-Haufen as 
biomarkers for diagnosing PVN had a 97% positive and 100% negative predictive value.18
After kidney transplantation, urinary PV-Haufen shedding follows a dynamic pattern closely 
reflecting the course of PVN.18 Furthermore, quantitative urinary PV-Haufen testing predicts 
intra-renal disease severity and the histologic PVN stages.20 Thus, urinary PV-Haufen reflect 
PVN and not lower urinary tract events. The objective of this pilot analysis was to determine 
whether urinary PV-Haufen testing could also be of diagnostic value after allogeneic HCT 
since the incidence of PVN, and its potential impact on renal failure in this patient cohort, is 
unknown.
In the current proof-of-concept study, urinary PV-Haufen testing post-HCT showed findings 
very similar to those previously described after renal transplantation.18, 20 The assay was 
feasible to perform according to established protocols.20 We found that PVN, based on the 
presence of PV-Haufen in the urine, was more common after HCT than previously thought, 
affecting one third of our study cohort. Urinary PV-Haufen were present in only a subgroup 
of patients with BK-viremia and not associated with hemorrhagic cystitis. Patients with 
detectable PV-Haufen had evidence of CKD and an increased risk for dialysis-dependent 
renal failure.
Close associations between urinary PV-Haufen shedding and renal histology were reported 
previously in kidney transplant recipients;18 such analyses are largely lacking in our HCT 
cohort due to the nature of the underlying disease preventing invasive diagnostic 
interventions and the collection of biopsies. Tissue specimens were only available from two 
patients that support our overall interpretation and analysis. One patient presented with 
abundant PV-Haufen shedding and histologic evidence of PVN at time of autopsy conducted 
shortly after testing. The second patient presented with minimal PV-Haufen shedding and no 
evidence of PVN at time of autopsy four weeks post-testing. We interpret findings made in 
the second patient not as contradictory but rather as expected and confirmatory since low 
PV-Haufen counts in the urine suggest low grade PVN with minimal productive intra-renal 
BK replication that resolved over four weeks until autopsy was conducted.20 Rapid 
resolution of PVN has been previously noted.18
Some patients in our pilot study demonstrated a mildly positive PV-Haufen test with only 
low level PV-Haufen shedding. If data collected in renal allograft recipients can be 
extrapolated to patients post-HCT, then this observation reflects a focal stage of PVN20 that 
might have good outcome and respond favorably to therapeutic interventions. Future studies 
are needed to further investigate this aspect.
Conventional PCR tests targeting BK virus gene sequences in urine or blood are often 
difficult to interpret. Overall, BK-viruria has a low positive predictive value for PVN or 
bladder injury in both kidney transplant and HCT recipients,17, 18, 23 as recently reviewed.10 
The kidney transplant literature suggests that BK-viremia, especially if persistent and/or 
high grade (>10,000 copies/mL), is “practically” synonymous with intrinsic kidney injury as 
virally-damaged tubules leak BK viral particles into the blood, where they are detected by 
PCR.9, 10, 16, 24, 25 However, whether this concept is, indeed, universally true and valid post-
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HCT is doubtful. For example, BK-viremia is not specific to kidney injury and may 
originate from extra-renal anatomic sites, such as the bladder (during hemorrhagic cystitis) 
or even salivary glands.23, 26 Post-kidney transplantation, only a subgroup of patients with 
BK-viremia will develop definitive, biopsy-proven disease (PVN) while most viremic 
episodes appear to be self-limiting, without urinary PV-Haufen shedding and without any 
clinical significance. In cases of PVN the level of BK-viremia by PCR only imperfectly 
reflects the severity of intra-renal disease.20 Last but not least, clinicians managing patients 
post-HCT usually interpret BK-viremia as a risk factor for hemorrhagic cystitis4, 5 and less 
for PVN. Thus BK-viremia does not necessarily equal “intra-renal” PVN.
In contrast to PCR-based BK assays, urinary PV-Haufen testing adds a new perspective to 
non-invasively and accurately identify patients with PVN, some of them presenting with 
concurrent hemorrhagic cystitis post-HCT (Table 1 and Figure 3). Since invasive procedures 
such as renal biopsies are often contraindicated after HCT due to the high bleeding risk, 
urinary PV-Haufen testing becomes particularly significant. From a clinical perspective, PV-
Haufen testing is relatively inexpensive (approximately US$300), has a turnaround time of a 
few hours, and can be performed in any laboratory with EM capability.18, 19 Accordingly, 
we hope that other investigators can learn to detect PV-Haufen at their laboratories and 
confirm our single-center observations.
Other than lowering immunosuppression, there is limited information on the optimal 
treatment for BK virus infection,27 and evidence is lacking that fluoroquinolones or 
leflunomide are effective agents against BK virus.28, 29 Intravenous cidofovir is associated 
with tubular toxicity and has not been thoroughly tested in PVN. New oral formulations of 
cidofovir are potentially less nephrotoxic but currently of undetermined effectiveness.27 In 
this context, urinary PV-Haufen testing may also help in future therapeutic trials, such as 
reserving potentially toxic treatment (i.e. cidofovir) to those patients with positive PV-
Haufen tests suggesting underlying PVN and avoiding it in those with negative test results.
Our observations are limited by the case-control analysis of pre-selected patients with 
relatively few data points. We did not have longitudinally collected samples in our patients; 
future research is needed to test for urinary PV-Haufen shedding, other signs of BK virus 
replication, and kidney function in a consecutive group of patients followed carefully at 
selected time points after HCT. To fully support the clinical utility of PV-Haufen testing, 
findings will have to be further confirmed by other investigators in the clinical context of 
confounding diseases impacting renal function.
In conclusion our results support a novel conceptual model for clinical testing and 
diagnosing disease associated with BK virus infection in HCT recipients (Figure 3). We 
believe that PVN is an under-recognized cause of kidney damage and CKD in children after 
HCT and that urinary PV-Haufen testing can identify patients with viral nephropathy. 
Larger, prospective studies are underway, systematically collecting urine samples at defined 
time points to further analyze the clinical significance of urinary PV-Haufen shedding and 
PVN on renal function and patient management post-HCT.
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Figure 1. Polyomavirus nephropathy after hematopoietic cell transplant
A) By routine electron microscopy (negative staining), a large polyomavirus Haufen 
(resembling a cast, arrow) is detected in a voided urine sample from a hematopoietic cell 
transplant recipient. B) Kidney autopsy specimen from a hematopoietic cell transplant 
recipient with detectable urinary polyomavirus Haufen. Tissue stained for BK virus using 
DNA in situ hybridization. Although the tissue is autolyzed, kidney tubules (arrow head) and 
tubular lumens (arrow) show positive staining for BK virus infected cells, defining 
polyomavirus nephropathy.
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Figure 2. Polyomavirus-Haufen detection in the urine, BK-viremia, and kidney function in the 
two hematopoietic cell transplant recipients who underwent autopsy
Both patient number 10 (top panel) and patient number 2 (bottom panel) had persistent BK-
viremia and a decreasing creatinine-estimated glomerular filtration rate concomitant with the 
detection of polyomavirus-Haufen in the urine.
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Figure 3. Conceptual model showing anatomical sources of BK virus infection after 
hematopoietic cell transplantation
In patients with hemorrhagic cystitis, bladder injury leads to release of viral particles in the 
urine (viruria) and blood (viremia). In this scenario, kidney function can be decreased if the 
bladder injury leads to urinary obstruction, but there is no intrinsic renal injury from BK 
virus/no polyomavirus nephropathy (PVN), and therefore urinary PV-Haufen cannot be 
detected. In patients with PVN, kidney tubular injury can lead to release of viral particles in 
the urine (viruria) and blood (viremia). Cast-like PV-Haufen form in virally injured renal 
tubules and can be detected in voided urine samples as specific biomarkers for “intra-renal” 
PVN.
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